Imaging Modalities for the Management of DME

What works best and what looks promising for the future.

By Yasha S. Modi, MD, and Justis P. Ehlers, MD
 

At a Glance

• For DME and vitreoretinal interface disorders associated with DR, OCT is the most useful imaging option.
• Fluorescein angiography maintains an important role in assessing leakage patterns that contribute to DME in patients with DR and for assessing the disease burden in the retinal periphery.
• OCT angiography is an emerging modality that may also enhance understanding of disease characteristics.

An estimated 18 million individuals in the United States are affected by diabetes mellitus, approximately 4% of whom also have diabetic macular edema (DME).1 This equates to about 700 000 individuals with DME.2 The Diabetes Control and Complications Trial reported that slightly more than one-fourth of type 1 diabetic patients developed DME within 9 years of disease onset.3 Those with type 2 diabetes have a similarly high rate, with 28% of individuals developing DME by 20 years after diagnosis.4

Although the mechanisms of DME development are complex, the end result is a breakdown of the inner blood-retina barrier (tight junctions between retinal vascular endothelial cells), which ultimately allows accumulation of mostly extracellular fluid in the retina. Once initiated, this process is typically chronic, resulting in potential long-term central vision loss.5

Figure 1. Ultra-widefield fundus photography in a patient with proliferative DR.

IMAGING OPTIONS

In the era before optical coherence tomography (OCT) imaging, the indication to treat macular edema via focal laser was based on a clearly defined standard established in the ETDRS, termed clinically significant macular edema.5 Since the time of the ETDRS, treatment modalities have expanded to include anti-VEGF therapy,6-9 steroids,10 and pars plana vitrectomy.11-13 In addition to the expansion of treatment options, the imaging technologies that complement the diagnosis and management of DME are now a critical component of the optimal approach to DME. An understanding of these imaging technologies is critical to delivering optimal care in the management of DME.

Fundus Photography

This established imaging modality provides important objective information regarding the severity of diabetic retinopathy (DR) and disease progression.14 It is also helpful for communication between physicians. Fundus photography can also serve as a useful tool for counseling patients on the extent of their retinopathy. Additionally, nonmydriatic ultra-widefield fundus photography provides excellent photos that can document disease severity throughout the posterior segment (Figure 1), and the introduction of this modality has improved detection of DR relative to standard fundus photography.15 As it pertains to DME, however, fundus photography is less useful for diagnosing and monitoring retinal thickening or macular edema.

Figure 2. OCT patterns in DME. Sponge-like thickening (A), cystoid macular edema (B), serous retinal detachment and intraretinal fluid in the absence of PHT (C), DME with PHT (D).

OCT

OCT has emerged as the most critical imaging test for DME as well as vitreoretinal interface disorders associated with DR. This sensitive imaging modality allows detailed evaluation of the retinal anatomy, the vitreoretinal interface, and the presence of retinal thickening, edema, or subretinal fluid. Although there is still no official classification of OCT-based DME, a number of informal classification schemes have been devised.16-19 OCT documents both qualitative and quantitative parameters, including the following:

• Retinal thickness at the fovea and parafoveal regions;

• Retinal morphology, such as sponge-like thickening (Figure 2A), diabetic cystoid macular edema (Figure 2B), serous retinal detachment without posterior hyaloidal traction (PHT; Figure 2C), and DME with associated PHT (Figure 2D);

• Retinal topography across the macular cube; and

• Presence or absence of vitreomacular adhesion or traction.

Additional OCT features that have been described to correlate with visual acuity and treatment response include the presence of an intact ellipsoid zone and external limiting membrane.20,21

Figure 3. Retinal thickness map in a patient with DME.

Figure 4. Retinal thickness change analysis.

Figure 5. DME secondary to PHT without traction retinal detachment.

Figure 6. Ultra-widefield fluorescein angiography demonstrating extensive peripheral nonperfusion and neovascularization.

The application of segmentation algorithms to OCT images allows accurate measurement of retinal thickness within the macular cube (Figure 3). Increased retinal thickness has been demonstrated to correlate with clinical biomicroscopic edema22 and fluorescein leakage patterns.16 There is also a modest correlation between visual acuity23 and increased retinal thickness. With the application of eye tracking software and retinal vessel recognition, retinal thickness maps can be compared across visits, and a change analysis can be generated (Figure 4). This information is helpful in assessing disease progression and treatment efficacy. Additionally, it may serve as an educational tool when patients are counseled on interval changes in their retinal status.

OCT also provides excellent resolution of the vitreoretinal interface and can identify DME with comorbid PHT (Figure 5). This condition, occurring in a distinct subgroup of patients, is often overlooked on biomicroscopic exam alone. These patients are often more resistant to medical therapy and may benefit from earlier surgical intervention to optimize visual outcomes.24

A novel use of OCT, particularly in patients with comorbid PHT or tractional retinal detachments, is as a guide for intraoperative decision-making. The technology may help facilitate the identification of surgical planes, define membrane relationships, and localize the presence of small full thickness breaks. Although it did not directly address diabetic surgery exclusively, the PIONEER study demonstrated that the use of intraoperative OCT potentially affected posterior segment surgical decision-making in a significant number of eyes.25

Fluorescein Angiography

Although studies have attempted to correlate OCT changes in patients with enlarged foveal avascular zones,26 a shortcoming of conventional OCT imaging is its inability to evaluate the presence or extent of macular ischemia. As a result, fluorescein angiography remains an essential part of the imaging armamentarium in DR for assessing the leakage pattern (focal or diffuse) contributing to DME. Variations in leakage may alter the treatment paradigm. For example, focal laser may be a beneficial treatment for extrafoveal focal leakage, while pharmacologic therapy with intravitreal anti-VEGF agents or steroids may be more effective in diffuse macular edema.27 Fluorescein angiography is also important in evaluating the extent of ischemia.

Figure 7. OCTA demonstrating microaneurysms with associated nonperfusion (A), foveal avascular zone irregularity and enlargement (B), and capillary nonperfusion and vascular remodeling (C).

Ultra-widefield fluorescein angiography confers the additional advantage of not only detecting macular leakage and ischemia, but also providing simultaneous evaluation of the extent of peripheral nonperfusion and occult peripheral neovascularization (Figure 6). Through the utilization of this technology, our understandings of the interconnections between peripheral nonperfusion, severity of DR, and responsiveness of macular edema are continuously evolving.

Using ultra-widefield fluorescein angiography, Wessel et al demonstrated a correlation between peripheral retinal ischemia and DME.28 Patients with retinal ischemia were 3.75 times more likely to develop DME relative to patients without retinal ischemia. Another study reported a correlation between recalcitrant DME and larger areas of peripheral nonperfusion, which suggests that targeted laser photocoagulation to the area of peripheral ischemia may serve as an adjunctive treatment for the management of DME.29 This is an area of active research and investigation.

OCT Angiography

This emerging imaging modality provides novel information compared with both conventional OCT and fluorescein angiography. OCT angiography (OCTA) utilizes an OCT scanner and a unique algorithm to identify areas of motion that correlate with vascular flow. It is a noninvasive, no-dye technique that captures the motion of particles (eg, red blood cells) within tissues. The motion signals can then be aggregated to provide a 3-D view of both the retinal and choroidal vasculature. Although OCTA does not provide leakage information, it reconstructs vascular flow patterns with detail that exceeds the imaging resolution of fluorescein angiography. Additionally, it can detail with precision the extent of microaneurysms (Figure 7A), the disruption of the foveal avascular zone (Figure 7B), and the extent of vascular remodeling (Figure 7C). This noninvasive modality is still in its infancy, and its specific role in the management of DME remains unclear. However, the high-quality image detail and noninvasive nature of OCTA makes it particularly attractive for assessing retinal vascular disorders such as DR.

CONCLUSION

Ophthalmologists and retina specialists have entered an exciting era of retinal imaging that provides accurate and highly reproducible information on retinal vascular leakage, retinal edema, and ischemia. Several multi- center randomized clinical trials have already implemented treatment and retreatment criteria based on imaging results that provide the clinician a framework to extrapolate into practice. OCT-guided therapy has become the gold standard to enable individualized treatment of conditions with multiple management options.

As clinicians become increasingly familiar with emerging technologies such as intraoperative OCT, ultra-widefield angiography, and OCTA, treatment paradigms will become more precise and tailored to each patient to yield the best possible outcomes. This is an exciting time in the evolution of our understanding of DME, and clinical studies are ongoing to determine the contribution of these new imaging modalities to improving outcomes. n

Justis P. Ehlers, MD, is an assistant professor of ophthalmology at the Cole Eye Institute at Cleveland Clinic and a consultant for Zeiss, Bioptigen, Leica, Alcon, ThromboGenics, and Alimera. He receives research support from Genentech, Regeneron, and ThromboGenics and has intellectual property licensed to Bioptigen. Dr. Ehlers may be reached at ehlersj1@yahoo.com.

Yasha S. Modi, MD, is a second-year fellow at the Cole Eye Institute. He has no relevant financial disclosures. Dr. Modi may be reached at yasha.modi@gmail.com.

1. Ding J, Wong TY. Current epidemiology of diabetic retinopathy and diabetic macular edema. Curr Diab Rep. 2012;12(4):346-354.

2. Jampol LM, Bressler NM, Glassman AR. Revolution to a new standard treatment of diabetic macular edema. JAMA. 2014;311(22):2269-2270.

3. [no authors listed] Progression of retinopathy with intensive versus conventional treatment in the Diabetes Control and Complications Trial. Diabetes Control and Complications Trial Research Group. Ophthalmology. 1995;102(4):647-661.

4. Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XV. The long-term incidence of macular edema. Ophthalmology. 1995;102(1):7-16.

5. Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology. 1991;98(5 Suppl):766-785.

6. Brown DM, Nguyen QD, Marcus DM, et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology. 2013;120(10):2013-2022.

7. Cunningham ET, Adamis AP, Altaweel M, et al. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology. 2005;112(10): 1747-1757.

8. Michaelides M, Kaines A, Hamilton RD, et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2. Ophthalmology. 2010;117(6):1078-1086.

9. Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119(4):789-801.

10. Boyer DS, Yoon YH, Belfort R, Jr., et al. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology. 2014;121(10):1904-1914.

11. Haller JA, Qin H, Apte RS, et al; Diabetic Retinopathy Clinical Research Network Writing Committee. Vitrectomy outcomes in eyes with diabetic macular edema and vitreomacular traction. Ophthalmology. 2010;117(6):1087-1093.

12. Otani T, Kishi S. A controlled study of vitrectomy for diabetic macular edema. Am J Ophthalmol. 2002;134(2):214-219.

13. Tachi N, Ogino N. Vitrectomy for diffuse macular edema in cases of diabetic retinopathy. Am J Ophthalmol. 1996;122(2):258-260.

14. Salz DA, Witkin AJ. Imaging in diabetic retinopathy. Middle East Afr J Ophthalmol. 2015;22(2):145-150.

15. Wessel MM, Aaker GD, Parlitsis G, et al. Ultra-wide-field angiography improves the detection and classification of diabetic retinopathy. Retina. 2012;32(4):785-791.

16. Kang SW, Park CY, Ham DI. The correlation between fluorescein angiographic and optical coherence tomographic features in clinically significant diabetic macular edema. Am J Ophthalmol. 2004;137(2):313-22.

17. Kim BY, Smith SD, Kaiser PK. Optical coherence tomographic patterns of diabetic macular edema. Am J Ophthalmol. 2006;142(3):405-412.

18. Otani T, Kishi S, Maruyama Y. Patterns of diabetic macular edema with optical coherence tomography. Am J Ophthalmol. 1999;127(6):688-693.

19. Panozzo G, Parolini B, Gusson E, et al. Diabetic macular edema: an OCT-based classification. Semin Ophthalmol. 2004;19(1-2):13-20.

20. Shin HJ, Lee SH, Chung H, Kim HC. Association between photoreceptor integrity and visual outcome in diabetic macular edema. Graefes Arch Clin Exp Ophthalmol. 2012;250(1):61-70.

21. Uji A, Murakami T, Nishijima K, et al. Association between hyperreflective foci in the outer retina, status of photoreceptor layer, and visual acuity in diabetic macular edema. Am J Ophthalmol. 2012;153(4):710-717.

22. Brown JC, Solomon SD, Bressler SB, et al. Detection of diabetic foveal edema: contact lens biomicroscopy compared with optical coherence tomography. Arch Ophthalmol. 2004;122(3):330-335.

23. Browning DJ, Glassman AR, Aiello LP, et al; Diabetic Retinopathy Clinical Research Network. Relationship between optical coherence tomography-measured central retinal thickness and visual acuity in diabetic macular edema. Ophthalmology. 2007;114(3):525-536.

24. Kaiser PK, Riemann CD, Sears JE, Lewis H. Macular traction detachment and diabetic macular edema associated with posterior hyaloidal traction. Am J Ophthalmol. 2001;131(1):44-49.

25. Ehlers JP, Dupps WJ, Kaiser PK, et al. The prospective intraoperative and perioperative ophthalmic imaging with optical coherence tomography (PIONEER) Study: 2-year results. Am J Ophthalmol. 2014;158(5):999-1007.

26. Lee DH, Kim JT, Jung DW, et al. The relationship between foveal ischemia and spectral-domain optical coherence tomography findings in ischemic diabetic macular edema. Invest Ophthalmol Vis Sci. 2013;54(2):1080-1085.

27. Massin P, Audren F, Haouchine B, et al. Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: preliminary results of a prospective controlled trial. Ophthalmology. 2004;111(2):218-224; discussion 24-25.

28. Wessel MM, Nair N, Aaker GD, et al. Peripheral retinal ischaemia, as evaluated by ultra-widefield fluorescein angiography, is associated with diabetic macular oedema. Br J Ophthalmol. 2012;96(5):694-698.

29. Patel RD, Messner LV, Teitelbaum B, et al. Characterization of ischemic index using ultra-widefield fluorescein angiography in patients with focal and diffuse recalcitrant diabetic macular edema. Am J Ophthalmol. 2013;155(6):1038-1044.


Tags:
 

Contact Info

Bryn Mawr Communications LLC
1008 Upper Gulph Road, Suite 200
Wayne, PA 19087

Phone: 484-581-1800
Fax: 484-581-1818

Karen Roman
Editor-in-Chief
484-581-1827
kroman@bmctoday.com

Janet Burk
Publisher
214-394-3551
jburk@bmctoday.com

About Retina Today

Retina Today is a publication that delivers the latest research and clinical developments from areas such as medical retina, retinal surgery, vitreous, diabetes, retinal imaging, posterior segment oncology and ocular trauma. Each issue provides insight from well-respected specialists on cutting-edge therapies and surgical techniques that are currently in use and on the horizon.